Trials / Recruiting
RecruitingNCT04547439
Sleep, Diabetic Retinopathy and Melatonin
Sleep and Circadian Regulation in Diabetic Retinopathy: The Role of Intrinsically Photosensitive Retinal Ganglion Cells and Melatonin Supplementation
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- University of Illinois at Chicago · Academic / Other
- Sex
- All
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study explores the use of melatonin in patients with diabetic retinopathy
Detailed description
This is a randomized controlled study using melatonin for 8 weeks in patients with diabetic retinopathy on outcomes of sleep and circadian regulation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Melatonin | Melatonin 3 mg will be taken nightly for 8 weeks |
| OTHER | Placebo | Placebo will be given nightly for 8 weeks |
Timeline
- Start date
- 2021-02-03
- Primary completion
- 2025-12-01
- Completion
- 2026-06-01
- First posted
- 2020-09-14
- Last updated
- 2025-08-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04547439. Inclusion in this directory is not an endorsement.